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In this issue of Immunity, Zelante et al. (2013) and Qiu et al. (2013) provide mechanistic insights into functional
interactions between commensal microbes and innate lymphoid cells via the aryl hydrocarbon receptor.Immunity at mucosal surfaces is a deli-
cate balance between tolerance and
response to the microbes that inhabit
these very unique ecological niches.
With the advent of metagenomics, we
have begun to appreciate the complexity
and diversity of the microbes (termed
the microbiota) that inhabit our body
and the multitude of mechanisms by
which they modulate the host response
and provide colonization resistance to
pathogens.
In the healthy gut mucosa, the micro-
biota are largely composed of anaerobes,
including Bacteroidetes and Firmicutes,
the latter of which comprises Clostridiales
and Lactobacillales. Members of these
phyla modulate mucosal immunity via
different mechanisms. Within the Bacter-
oidetes phylum, Bacteroidales ferment
fiber to short-chain fatty acids and release
polysaccharides that enhance colonic
health and have immunomodulatory func-
tions that result in mucosal homeostasis.
Similarly, Clostridia-related species, like
segmented filamentous bacteria (SFB),
modulate the host response by inducing
intestinal T helper 17 (Th17) cells, whereas
other Clostridia species induce T regula-
tory cells, although the molecular mecha-
nisms for these effects are unknown.
In this issue, two elegant studies by
Zelante et al. (2013) and Qiu et al. (2013)
further contribute to our understanding
of the complex interplay between com-
mensal microbes and group 3 innate
lymphoid cells (ILC3s) expressing the
aryl hydrocarbon receptor (Ahr) (Figure 1).
ILC3s secrete interleukin-22 (IL-22) and
were shown to control infection with the
mouse intestinal pathogen Citrobacter
rodentium and to prevent dissemination
of commensal Alcaligenes spp. But how
are ILCs activated?206 Immunity 39, August 22, 2013 ª2013 ElsZelante et al. (2013) show that a subset
of commensal Lactobacilli (L. reuteri in
the stomach and L. acidophilus in the
vaginal tract) utilize tryptophan as an en-
ergy source and produce a metabolite,
indole-3-aldeyde (IAld), which activates
Ahr in innate lymphoid cells (ILCs). In
turn, ILCs release IL-22, which induces
an antimicrobial response that reduces
colonization of the opportunistic path-
ogen Candida albicans. One of the most
remarkable findings of this study is that
not all Lactobacilli can utilize tryptophan
and release IAld despite the fact that
araT is present in the genome; the protein
product of araT converts the tryptophan
derivative indole pyruvate to IAId.
L. johnsonii, for example, has an intact
araT homolog, although this gene is not
upregulated in tryptophan rich media
and IAId is not produced. What emerges
from this study is that differences in
gene expression even within the same
genus might determine which microbial
species is better adapted to colonize a
niche.
The authors showed by analysis of the
microbiota that when tryptophan is less
abundant, L. johnsonii is the predominant
species. Conversely, when tryptophan
is abundant (for instance, in mice lack-
ing indoleamine 2,3-dioxygenase, the
enzyme for tryptophan degradation),
IAld-producing species like L. reuteri pre-
dominate. As a result, Ahr activation in
ILCs leads to the release of IL-22, which
protects the host from colonization by
C. albicans. The mechanistic link between
ILC stimulation and a product of trypto-
phan catabolism was elegantly demon-
strated with experiments showing that
an L. reuteri araT mutant was unable
to maximally stimulate ILCs to produce
IL-22. Moreover, only colonization ofevier Inc.germ-free mice with wild-type L. reuteri,
but not with a mutant in araT or with
L. johnsonii, induced resistance to
C. albicans. Overall, this study suggests
that use of probiotic Lactobacilli to
reduce colonization and infection with
C. albicans might be possible. A potential
future direction includes the identification
of the mechanisms by which IL-22 and
ILCs protect the host against infection
with C. albicans.
Consistent with other studies, the
authors showed that IL-22 induces ex-
pression of the antimicrobial protein
lipocalin-2 and of the two subunits of
calprotectin, S100A8 and S100A9 (Liu
et al., 2009). These proteins are com-
ponents of the host response that se-
questers essential metal ions to reduce
their availability to pathogens, a concept
known as nutritional immunity (Hood and
Skaar, 2012). Lipocalin-2 binds to a sub-
set of catecholate siderophores, small
iron chelators secreted by bacteria, to
obtain iron from the host. Although
C. albicans is not susceptible to lipoca-
lin-2 (Liu et al., 2009), calprotectin has
been shown to inhibit the growth and
colonization of this opportunistic path-
ogen by sequestering zinc and manga-
nese (Urban et al., 2009). On the basis
of these observations, it is possible that
IL-22-dependent secretion of calprotectin
reduces C. albicans colonization. Intrigu-
ingly, Lactobacilli in general are not
affected by IL-22-dependent antimicro-
bial responses, given that their overall
colonization is not reduced when ILCs
are activated.
Not all gut commensals remain unaf-
fected by the actions of IL-22, as Qiu
et al. (2013) have shown through a series
of experiments with SFB. They eluci-
dated that Ahr- and RorgT-dependent
Figure 1. Mechanisms of Interaction between Commensal Microbes and ILCs via Ahr
Zelante et al. demonstrated that Lactobacilli in the stomach and vagina utilize Tryptophan (Trp) and
convert it to indole-3-aldehyde (IAld). IAId enters the mucosa and reaches group 3 ILCs (ILC3s) via
unknown pathways. In ILC3s, IAld serves as a ligand for Ahr. Ahr enhances the expression of IL-22 in
ILC3s, which in turn stimulates epithelial cells to produce antimicrobial proteins like lipocalin-2, calprotec-
tin (a heterodimer of S100A8 and S100A9), and RegIIIg. As a result, Candida albicans colonization is
reduced, possibly because of its susceptibility to calprotectin-mediated growth inhibition. Qiu et al.
showed that Ahr and retinoid-related orphan receptor g (RORgt) induce the expression of IL-22 in the small
intestine, which limits expansion of SFB. This might also be due to the action of antimicrobial proteins
that are induced by IL-22. Reduced levels of SFB result in a reduced amount of inflammatory inter-
feron-g (IFN-g)- and IL-17-producing CD4+ T cells in the gut mucosa, protecting mice from exacerbated
experimental colitis. Reduced colitis might also benefit SFB, given that related obligate anaerobes
(Clostridiales) succumb to the intestinal inflammatory environment (not shown). Bold downward arrows
indicate reduced colonization or cell number. Artwork by Janet Z. Liu.
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Previewsexpression of IL-22 by ILCs is crucial to
limiting SFB colonization and the accom-
panying and potentially harmful exacer-
bated expansion of IL-17-producing cells.
When IL-22 amounts were increased by
injection of recombinant IL-22, SFB colo-
nization decreased, whereas antibody-
mediated depletion of IL-22 resulted in
increased SFB colonization. In addition,
IL-22 from a specific source (Ahr+ RorgT+
ILCs) was deemed crucial to controlling
SFB colonization, given that a lack of
ILCs resulted in higher numbers of SFB
and, consequently, higher numbers of
IL-17-producing cells than in littermate
controls. Remarkably, Ahr-deficient mice
developed exacerbated colitis in a
T-cell-transfer model, which was sub-
stantially ameliorated by treatment with
antibiotics that reduced SFB numbers.
These exciting findings are potentially
relevant to inflammatory bowel disease(IBD) because lower-than-average Ahr
amounts were recently detected in IBD
patients (Monteleone et al., 2011). The
question still remains, however, how
IL-22 reduces SFB colonization.
One antimicrobial peptide that is
secreted by intestinal epithelial cells in
response to IL-22 is the C-type lectin
RegIIIg, which has strong antimicrobial
activity against Gram+ bacteria. The
observations that SFB colonization in-
creases in RegIIIg-deficient mice (Vaish-
nava et al., 2011) and that Ahr-deficient
mice express lower amounts of RegIIIg
(Qiu et al., 2012) suggest that this anti-
microbial lectin reduces the growth of
SFB. In conditions of gut homeostasis,
Ahr+ RorgT+ ILCs secrete IL-22, which
limits the proliferation of SFB. If this
pathway is altered, the excessive
increase of SFB and of pathogenic Th17
cells results in colitis, the recruitment ofImmunity 39neutrophils, and major alterations in the
intestinal environment. As a result, the
growth of anaerobes such as Bacteroi-
detes and Clostridiales (SFB included)
would be substantially reduced. In
contrast, facultative anaerobes such as
Proteobacteria would proliferate because
they can utilize nitrate, a by-product
of the host inflammatory response, for
respiration (Winter et al., 2013). Thus,
the ILC-mediated control of pathogenic
Th17 cell expansion is essential for main-
taining a healthy gut and healthy levels
of colonization with anaerobes.
We are at the beginning of understand-
ing the complex interplay between the
host and the microbiota, elucidating the
mechanisms by which host-microbe
interactions provide colonization resis-
tance to pathogens. The two studies
highlighted here substantially enhance
our understanding of this complex picture
by shining light on the role of ILCs, Ahr,
and IL-22 in modulating the composition
of the microbiota.REFERENCES
Hood, M.I., and Skaar, E.P. (2012). Nat. Rev.
Microbiol. 10, 525–537.
Liu, J.Z., Pezeshki, M., and Raffatellu, M. (2009).
Cytokine 48, 156–160.
Monteleone, I., Rizzo, A., Sarra, M., Sica, G., Sileri,
P., Biancone, L., MacDonald, T.T., Pallone, F., and
Monteleone, G. (2011). Gastroenterology 141,
237–248.
Qiu, J., Heller, J.J., Guo, X., Chen, Z.M., Fish, K.,
Fu, Y.X., and Zhou, L. (2012). Immunity 36, 92–104.
Qiu, J., Guo, X., Chen, Z.-m.E., He, L., Sonnen-
berg, G.F., Artis, D., Fu, Y.-X., and Zhou, L.
(2013). Immunity 39, this issue, 386–399.
Urban, C.F., Ermert, D., Schmid, M., Abu-Abed, U.,
Goosmann, C., Nacken, W., Brinkmann, V., Jung-
blut, P.R., and Zychlinsky, A. (2009). PLoS Pathog.
5, e1000639.
Vaishnava, S., Yamamoto, M., Severson, K.M.,
Ruhn, K.A., Yu, X., Koren, O., Ley, R., Wakeland,
E.K., and Hooper, L.V. (2011). Science 334,
255–258.
Winter, S.E., Winter, M.G., Xavier, M.N., Thienni-
mitr, P., Poon, V., Keestra, A.M., Laughlin, R.C.,
Gomez, G., Wu, J., Lawhon, S.D., et al. (2013).
Science 339, 708–711.
Zelante, T., Iannitti, R.G., Cunha, C., De Luca, A.,
Giovannini, G., Pieraccini, G., Zecchi, R., D’Angelo,
C., Massi-Benedetti, C., Fallarino, F., et al. (2013).
Immunity 39, this issue, 372–385., August 22, 2013 ª2013 Elsevier Inc. 207
